Morning Brief — Monday, August 3, 2026

Market Overview

Markets are opening higher Monday as President Trump’s announcement of upcoming Iran negotiations eases geopolitical tensions that had weighed on sentiment, with SPY futures up ~0.5% pre-bell. The mega-cap tech earnings cycle delivered mixed results — Amazon surged 15%+ on AI infrastructure momentum while WDC, AMD, and ANET sold off despite solid prints, suggesting the bar remains extremely high for hardware names. The 10-year Treasury yield topping 4.7% (its highest since January 2025) creates a headwind for high-multiple growth names even as the earnings season broadly trends positive.

Claude’s Call

UP — The Iran truce narrative removes the single biggest overhang from last week, and Amazon’s blowout print provides a powerful AI tailwind that lifts the entire hyperscaler ecosystem; expect the S&P to grind higher intraday, with defensives lagging and tech/industrials leading.

Top Movers

IESC (+30.3%) — $744.54 → $865.62 (+16.3% upside) Thesis: IES Holdings delivered a monster earnings beat with a strong AI data center outlook, and Goldman’s recent Buy initiation added institutional credibility to the story. This is a genuine “picks and shovels” AI play — electrical contractors are capacity-constrained as hyperscalers race to build, and IESC just confirmed the backlog is real. The stock just printed a fresh 20-day high at $744.54 and is breaking toward its 6-month high of $766.54, with the Fib 1.272 extension at $865.62 as the next logical target. RSI at 15.81 is anomalously low for a stock up 30% — this data point looks erroneous, so I’d treat momentum as the primary signal here. Volume ratio is thin (0.05x avg), which is the one concern: this move needs follow-through buying to sustain. Levels: Exit at Fib 1.272 extension $865.62. Support at 23.6% Fib retracement $680.58 and 50-day SMA $674.31.

ATKR (+28.1%) — $93.47 → $103.80 (+11.0% upside) Thesis: Atkore is a done deal — Prysmian agreed to acquire the company at $95/share, and ATKR printed a simultaneous earnings beat (+30.6% EPS surprise, +5% revenue). At $93.47, the stock is trading at a small discount to the $95 deal price, which is classic merger arbitrage spread territory (~1.6%). The upside is bounded by the deal terms unless a competing bid emerges, but volume ratio at 4.57x confirms this is real institutional flow, not noise. Don’t expect 11% upside here — the realistic trade is capturing the ~$1.50 arb spread and moving on. Technically, this is a 6-month high breakout with no meaningful resistance until the deal closes. Levels: Exit at deal price $95.00 (hard ceiling absent competing bid). Support at 23.6% Fib $84.34.

AMZN (+15.3%) — $271.58 → $308.17 (+13.5% upside) Thesis: Amazon’s Q2 was a genuine blowout — AWS AI momentum is accelerating, advertising continues to surprise, and the market is rightly repricing the stock higher after what appears to be a significant EPS and revenue beat. At $271.58, AMZN has broken to a new 6-month high (prior high $284.78 was just eclipsed intraday), and the Fib 1.272 extension at $308.17 is a clean target for a continued run. The RSI at 11.14 looks like a data artifact for a stock gapping up 15% — momentum is clearly bullish. One caution: the news highlights that Amazon is borrowing to fund AI capex while Microsoft pays cash — that’s a longer-term watch item, but irrelevant to today’s tape. Levels: Exit at Fib 1.272 extension $308.17. Support at 23.6% retracement $264.49 and 50-day SMA $247.02.

AMBA (+16.1%) — $86.00 → $105.79 (+23.0% upside) Thesis: NXP Semiconductors is reportedly in acquisition talks for Ambarella at a valuation north of $3 billion — this is the second leg of a deal rumor that first broke July 31. At $86, AMBA is still 8% below its 6-month high of $93.57, meaning there’s legitimate deal-premium runway if NXP comes in at or above prior highs. The Fib 1.272 extension at $105.79 aligns roughly with a deal premium scenario. Key risk: M&A rumors fail to close ~40% of the time — if NXP walks, this stock retraces to the $65-72 range (Fib 50%-61.8% support). The 50-day SMA at $72.95 is the real stop-loss level for anyone buying the rumor. Levels: Exit at 6-month high $93.57 first, then Fib 1.272 $105.79 if deal confirms. Support at 23.6% Fib $82.97 and 50-day SMA $72.95.

DXCM (+11.9%) — $83.45 → $94.34 (+13.1% upside) Thesis: DexCom raised full-year 2026 revenue guidance to $5.18-5.25B (implying 11-13% growth), beat Q2 revenue by ~13% YoY, and expanded margins — this is a clean triple with legitimate fundamental legs. The Type 2 diabetes non-insulin expansion is a structural TAM story that the market was undervaluing. At $83.45, DXCM is at a 6-month high with the Fib 1.272 extension at $94.34 as the next resistance target. The 50-day SMA at $73.43 provides a comfortable cushion below — there’s 13% upside to the next fib target with only 12% downside to the SMA. Levels: Exit at Fib 1.272 extension $94.34. Support at 23.6% Fib $79.65 and 50-day SMA $73.43.

PWP (+18.4%) — $17.65 → $26.73 (+51.5% upside) Thesis: Perella Weinberg crushed Q2 EPS ($0.20 actual vs. $0.06 estimate — more than triple expectations) on flat revenue, driven by cost discipline and a larger M&A advisory backlog weighted toward H2. This is a legitimate earnings inflection story for an independent advisory boutique that benefits directly from the M&A deal surge we’re seeing (ATKR/Prysmian today is one example). RSI at 7.86 looks like a data anomaly for a stock up 18%, but the stock is still well below its 6-month high of $24.16 — meaning there’s meaningful room to recover lost ground. Management guiding for H2 weighting is the key line — if the deal backlog converts, Q3 will be another beat. Levels: Exit at 6-month high $24.16 first, then Fib 1.272 $26.73. Support at 61.8% Fib $18.32 and 50-day SMA $16.11.

CDNA (+14.7%) — $43.71 → $53.79 (+23.0% upside) Thesis: CareDx delivered a surgical 52% revenue growth quarter ($132M) and beat EPS by 68% — the NavDx oncology platform acquisition is diversifying the company beyond transplant diagnostics into precision oncology, which materially expands the TAM. At $43.71, the stock is at a fresh 6-month high, and the Fib 1.272 extension at $53.79 is a reasonable 6-8 week target. The 50-day SMA is back at $28.83 — this stock has run hard from the lows, so position sizing matters. The divested lab products business is a positive clean-up of the portfolio. Levels: Exit at Fib 1.272 $53.79. Support at 23.6% Fib $38.72 — a wide range, so size accordingly.

SUPN (+16.4%) — $51.93 → $59.79 (+15.1% upside) Thesis: Supernus beat Q2 revenue by 6.8% and announced an all-stock merger with Indivior — this is a strategic combination in CNS/addiction medicine that creates a more diversified specialty pharma platform. The EPS print matched estimates exactly (no beat, no miss on earnings), but the revenue beat plus the deal premium is doing the heavy lifting. At $51.93, SUPN has room to the Fib 1.272 extension at $59.79 and is approaching but not at the 6-month high of $56.32. The merger introduces deal-execution risk — all-stock transactions can be volatile if INDV’s stock moves adversely. Levels: Exit at Fib 1.272 $59.79. Support at 38.2% Fib $51.45 (nearly current price — tight stop) and 50-day SMA $46.42.

Headlines to Watch

“Atkore Agrees to Be Acquired by Prysmian in $3.8 Billion Deal” — Pure merger arb at $93.47 vs. $95 deal price; the real question is whether any competing bidder emerges in the electrical products space given the AI infrastructure buildout demand.
“Microsoft Pays Cash. Amazon Borrows. Here’s How Big Tech Funds Its AI Boom.” — Diverging balance sheet strategies matter for long-duration investors; Amazon’s leverage bet on AI works brilliantly if AWS growth accelerates, but adds risk in a higher-for-longer rate environment with the 10Y at 4.7%.
“NXP Buyout Talks For Self-Driving Chip Maker [AMBA]” — The semi M&A cycle is accelerating; watch for read-through to other small/mid-cap AI chip names (OUST, CEVA, others) as consolidation plays.
“MakeMyTrip Q1 Earnings: Hotels/Packages Offset Air Weakness” — Indian travel demand remains structurally robust; India unit IPO filing is the bigger catalyst watch — that could reprice MMYT significantly higher if the domestic listing gets done.
“Apple’s Record Quarter Ran Into A Memory Bill” — Apple’s memory cost headwind is a direct read-through warning for WDC/SNDK bulls — if the largest memory customer is signaling cost inflation, the narrative that memory pricing is in a sweet spot needs revisiting.
“Supernus and Indivior to Merge in All-Stock Deal” — CNS/addiction pharma consolidation is a theme; check INDV reaction for the other side of this trade, as all-stock deals often create a short-the-acquirer, long-the-target dynamic.
“US-Iran Truce Hopes Lift Futures” — Classic geopolitical relief rally setup; historically these moves fade within 48-72 hours unless backed by actual policy agreements, so treat today’s gap-up with appropriate skepticism if you weren’t already long.

Claude’s Top Picks

DXCM (+11.9% today, +16.7% week) — $83.45 → $94.34 (+13.1% upside) Valuation: Trading at a discount to CGM peers on a growth-adjusted basis given the TAM expansion into non-insulin Type 2 patients, which meaningfully changes the addressable market narrative. Upside: Raised full-year guidance + margin expansion + new patient cohort expansion = a multi-quarter re-rating story, not just a one-day pop; the Fib 1.272 extension at $94.34 is achievable within 2-3 weeks. Risk: Any hiccup in the Type 2 reimbursement pathway or a GLP-1 drug narrative shift could pressure CGM adoption sentiment hard and fast.

PWP (+18.4% today, +12.6% week) — $17.65 → $24.16 (+36.8% upside) Valuation: Independent advisory boutiques like PWP, Lazard, and Evercore trade at premium multiples in active M&A environments; PWP at ~$17 still sits 27% below its 6-month high of $24.16, making it the cheapest it’s been relative to deal activity in years. Upside: H2 2026 is management’s own guidance for back-weighted results, and today’s M&A deal flow (ATKR/Prysmian, SUPN/INDV) validates the pipeline commentary — if deal volume stays elevated, PWP is materially undervalued. Risk: A sudden risk-off event (escalating geopolitics, credit tightening) could freeze the M&A market overnight and vaporize the backlog conversion thesis.

AMZN (+15.3% today, +17.0% week) — $271.58 → $308.17 (+13.5% upside) Valuation: At the current price, AMZN’s AWS segment alone likely justifies the valuation — the advertising business growing double-digits is essentially a free call option that peers would trade at 15-20x revenue standalone. Upside: Breaking to a new 6-month high on monster volume after a genuine fundamental beat; the Fib 1.272 extension at $308.17 is the next clean resistance, and large-cap momentum tends to persist for 2-3 weeks post-earnings breakout. Risk: The 10Y at 4.7% is a real multiple compressor for long-duration growth names, and AMZN’s borrowing-to-fund-AI-capex strategy looks fine in a bull scenario but ugly if rates stay elevated and AWS growth disappoints in Q3.

CDNA (+14.7% today, +17.7% week) — $43.71 → $53.79 (+23.0% upside) Valuation: Post-NavDx acquisition, CDNA’s revenue mix is shifting toward higher-margin oncology testing — comparable precision diagnostics companies (Veracyte, Guardant) trade at 6-8x revenue vs. CDNA’s more modest multiple, suggesting room for re-rating as oncology becomes a larger revenue mix. Upside: 52% revenue growth with a 68% EPS beat is a rare combination in diagnostics — institutional funds that missed the move will be forced to add on pullbacks, creating a natural bid under the stock. Risk: The rapid transition from transplant-pure-play to a multi-platform diagnostics company introduces integration execution risk, and the 6-month high breakout at $45.72 could act as resistance before further extension.

ARXS (+10.9% today, +28.1% week) — $54.30 → $62.07 (+14.3% upside) Valuation: A recently IPO’d aerospace/defense name with 25% revenue growth and 38% EBITDA expansion — if comparable defense/industrial tech names trade at 15-20x EBITDA, the raised guidance suggests ARXS has meaningful upside from current levels. Upside: Q2 beat on record sales with guidance raised — this is a clean fundamental story in a sector (aerospace/defense) that gets multiple tailwinds from geopolitical tension; the Fib 1.272 extension at $62.07 is the near-term target. Risk: Very recent IPO means limited institutional ownership history, wide bid-ask spreads, and minimal float — these can crash as fast as they run, and the week-over-week +28% move means a lot of fast money is already in.

Avoid

IESC — Up 30% on a single day’s move to a fresh 20-day high of $744.54, already past the 6-month high of $766.54 at intraday peaks, with volume ratio at only 0.05x average — this is a thin-market, parabolic extension with no conviction volume to sustain it; wait for a pullback to the 23.6% Fib at $680.58 or the 50-day SMA at $674.31 before initiating.

ALVO — Up 15.4% on the week but still a sub-$5 biosimilar name that has declined 64% over five years; the recent $240M capital raise is dilutive, and FDA pipeline risk on AVT16 is binary — this is speculative noise in a risk-on tape, not a fundamental catalyst, and the RSI/momentum data provides no edge here.

KC (Kingsoft Cloud) — The RSI at 1.87 is the most extreme reading in the dataset and combined with +9.96% on the day with no fresh company-specific news (latest catalyst was a July analyst initiation weeks ago), this looks like a low-float sympathy rally on China tech optimism — without a fundamental driver today, these moves in Chinese ADRs historically fade within 24-48 hours.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — WDC’s -5.16% post-earnings reaction despite strong results is a yellow flag for MU bulls; at $777 with the 50-day SMA at $965 and the stock sitting in the middle of a $321-$1,213 6-month range, this is value-trap territory until memory pricing data confirms the upcycle thesis rather than just AI demand hype.

SNDK — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — SNDK reported $29.28 EPS and got punished -2.51%, which is a classic “sell the news” signal for a stock that ran hard into earnings; at $1,171 vs. the 50-day SMA at $1,704, SNDK is in a deep technical downtrend and the analyst target at $2,217 offers no near-term anchor — this is WSB fighting a tape that doesn’t care about their thesis yet.

RDDT — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — Reddit is sitting at $144 vs. its 6-month high of $203 and the 50-day SMA at $175; the technicals are bearish (price below all key MAs) and there’s no fresh catalyst today — WSB is long their own platform in a classic conflict-of-interest trade, and the chart says fading this below $152 (61.8% Fib) is the higher-probability play.

SPCX — WSB says: MIXED (55% bullish) Claude says: AGREE with the ambivalence — SpaceX reported -$0.67 EPS (a loss) and the stock fell 1.39% post-earnings; at $106.57 vs. a recent high of $211.39, SPCX has been cut in half from its peak and the Fib 50% support at $158.98 is nowhere near current price — the loss-making reality is finally hitting the narrative premium, and 55% bullish is probably 10 points too high still.

NVDA — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — NVDA at $199 is trading right at the Fib 50% support level ($200.22) from the 6-month range, which is actually a reasonable technical entry for a bounce; the 50-day SMA at $205 is just overhead resistance, and the structural AI demand story is intact — but the stock is in a clear short-term downtrend (below $205 SMA, below $218 23.6% Fib), so the entry is fair but the timing is early, not obvious.

Earnings Scorecard

WDC — REPORTED | EPS: $16.73 | Stock: -5.16% | Reaction: SELL THE NEWS — JUSTIFIED Strong EPS but the -5% reaction reflects that memory investors need forward guidance to confirm pricing durability, not just a backward-looking print; with Apple flagging memory cost headwinds, the bull case for WDC needs more evidence before re-entry.

ANET — REPORTED | EPS: $2.90 | Stock: -2.83% | Reaction: SLIGHTLY OVERDONE Arista raised 2026 guidance and cited AI demand momentum — a -2.8% reaction on raised guidance is probably 1-2% too harsh; the stock has a history of digesting beats poorly in the near term before resuming its uptrend, making this a buy-the-dip candidate at the right level.

AMD — REPORTED | EPS: $3.00 | Stock: -2.80% | Reaction: JUSTIFIED AMD’s AI GPU ramp continues but NVIDIA’s moat in training workloads remains dominant; -2.8% on a solid print reflects the reality that AMD is a “good story, wrong stock” for the AI trade until MI300X market share data proves otherwise. Analyst target at $579 suggests substantial upside on a longer timeline, but near-term catalysts are thin.

DIS — REPORTED | EPS: $6.25 | Stock: +2.61% | Reaction: INSUFFICIENT — BUY THE DIP Disney beat with $6.25 EPS vs. the pattern of recent quarters, and a +2.6% move feels modest relative to the print quality; streaming profitability expansion + parks resilience = a stock that should be rerating higher; the analyst target at $126.51 implies meaningful upside from current levels.

BP — REPORTED | EPS: $1.23 | Stock: -2.59% | Reaction: JUSTIFIED Oil majors remain trapped between soft crude prices and elevated capex commitments; BP’s -2.59% move reflects the market’s ongoing skepticism about the energy transition strategy and the oil price outlook at current levels.

SNDK — REPORTED | EPS: $29.28 | Stock: -2.51% | Reaction: JUSTIFIED Strong headline number but the tape is telling you expectations were even higher; with the stock 50% below its recent highs, this is a technical downtrend that an in-line earnings print won’t reverse — need positive forward guidance catalysts to change the structure.

SHOP — REPORTED | EPS: $1.02 | Stock: +2.17% | Reaction: INSUFFICIENT — MODEST BUY Shopify has a history of dropping on beats (per the headline noting a 16% drop after its last earnings beat), so a +2.17% muted reaction is actually relatively positive — the market is learning not to sell Shopify beats indiscriminately; analyst target at $148 implies 20%+ upside.

CNQ — REPORTED | EPS: $4.04 | Stock: -2.13% | Reaction: JUSTIFIED Canadian energy names remain at the mercy of WTI/WCS spreads and CAD/USD dynamics; no reason to fight this tape with oil soft and Iran tensions easing (reducing the geopolitical premium).

WMB — REPORTED | EPS: $2.28 | Stock: -2.03% | Reaction: SLIGHTLY OVERDONE Midstream infrastructure with steady distributable cash flow shouldn’t be down 2% on a reported print — this looks like sector rotation out of energy more than a stock-specific issue; WMB’s pipeline assets are AI data center power infrastructure adjacent, which is an underappreciated long-term tailwind.

MELI — REPORTED | EPS: $37.93 | Stock: +2.01% | Reaction: INSUFFICIENT — BUY MercadoLibre printing $37.93 EPS and only getting +2% is a market that’s not paying attention; MELI is the Amazon + PayPal of Latin America with structural e-commerce and fintech penetration tailwinds — analyst target at $2,214 vs. the current reaction suggests the market is being too cautious.

PLTR — REPORTED | EPS: $0.89 | Stock: +1.68% | Reaction: INSUFFICIENT Palantir’s AI platform government contracts are accelerating and a +1.68% reaction feels like the market is underreacting to what has been a consistently strong executor — however, at a premium valuation, the stock needs to prove commercial segment re-acceleration to break out of its current range.

MCD — REPORTED | EPS: $12.12 | Stock: +1.67% | Reaction: JUSTIFIED McDonald’s is a defensive compounder — a modest +1.67% on a beat is appropriate; the real question is whether value-meal traffic recovery is durable or a one-quarter phenomenon as consumers remain stretched.

APP — REPORTED | EPS: $11.48 | Stock: +1.54% | Reaction: UNDERDONE — BUY AppLovin posting $11.48 EPS is genuinely impressive for an adtech platform; the muted +1.54% reaction may reflect position sizing ahead of the print — analyst target at $654 implies the market is undervaluing the consumer segment growth optionality.

SPCX — REPORTED | EPS: -$0.67 | Stock: -1.39% | Reaction: INSUFFICIENT — MORE DOWNSIDE LIKELY SpaceX losing $0.67/share on its first public earnings report is a reality check for the $200+ peak price crowd; -1.39% is too gentle a reaction for a loss-making company trading at an extreme narrative premium relative to peers — the chart agrees, already down 50% from highs.

PFE — REPORTED | EPS: $1.31 | Stock: +1.20% | Reaction: FAIR Pfizer is in a multi-year post-COVID revenue reset — a +1.2% reaction on a modest beat reflects the appropriate level of skepticism; the $28.74 analyst target vs. current price suggests the stock is range-bound until a new pipeline catalyst emerges.

This brief is for informational purposes only and does not constitute investment advice. All technical levels are derived from the data provided. Always size positions according to your own risk tolerance.